Frontage (HKG:1521) recorded a net profit of $0.2 million for the nine months ended Sept. 30, lower than the $9.8 million net profit logged for the corresponding period last year, a Tuesday filing with the Hong Kong Exchange said.
The laboratory and related services provider's revenue for the nine months was $191.1 million, 3.6% lower than HK$XX billion booked a year ago.
The detailed financial results of the company are disclosed in the unaudited third-quarter results for 2024 of the company's controlling shareholder, Hangzhou Tigermed Consulting (HKG: 3347, SHE:300347).
The company's shares were down over 1% on Tuesday's close.
Price (HKD): $0.73, Change: $-0.010, Percent Change: -1.35%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。